HPTN 083 is a research study that compares the effectiveness of injections
and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV.
HPTN 083 is a study that is part of the NIH-DAIDS-funded HIV Prevention Trials Network (HPTN). Learn more under Additional Information.
CABOTEGRAVIR FOR PREP
HPTN 083 is the first large-scale clinical trial of a long-acting injectable drug for HIV prevention. The study is examining whether a long-acting form of the anti-HIV drug cabotegravir injected once every 8 weeks can safely protect people from getting HIV infection at least as well as another anti-HIV medication combination taken as an oral tablet daily. The oral tablet, called Truvada, consists of the two anti-HIV drugs – emtricitabine and tenofovir disoproxil fumarate (TDF/FTC).